Open AccessAssociation Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes
Author(s) -
Anna R. Kahkoska,
Trine Julie Abrahamsen,
G. Caleb Alexander,
Tellen D. Bennett,
Christopher G. Chute,
Melissa A. Haendel,
Klara R. Klein,
Hemalkumar B. Mehta,
J. D. Miller,
Richard A. Moffitt,
Til Stürmer,
Kajsa Kvist,
John B. Buse
Publication year - 2021
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/1yfd-sc03
Subject(s) - glucagon like peptide 1 receptor , glucagon like peptide 1 , agonist , covid-19 , endocrinology , receptor , chemistry , medicine , pharmacology , diabetes mellitus , type 2 diabetes , disease , infectious disease (medical specialty)